A New Chapter in Rare Disease Treatment: Omeros and Novo Nordisk Finalize Landmark Zaltenibart Deal
Biotech's Vanguard: Novo Nordisk, Omeros, and GSK Charting New Territories in Medical Innovation
Omeros Stock Skyrockets: Novo Nordisk Seals Massive $2.1 Billion Rare Disease Drug Deal